Product Description
Moxifloxacin is used to treat bacterial infections in many different parts of the body. It is also used to treat and prevent plague (including pneumonic and septicemic plague). Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. (Sourced from: https://www.mayoclinic.org/drugs-supplements/moxifloxacin-oral-route/side-effects/drg-20072313?p=1)
Mechanisms of Action: HERG Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Plague | Pneumonia, Bacterial | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis | Chlamydia Infections | Conjunctivitis, Bacterial | Corynebacterium Infections | Escherichia coli Infections | Haemophilus Infections | Klebsiella Infections | Pneumonia, Bacterial | Trachoma | Conjunctivitis | Pneumonia | Influenza, Human
Known Adverse Events: Bradycardia | Myocardial Ischemia | Dizziness | Headache | Myasthenia Gravis | Drug Hypersensitivity | Hypersensitivity, Immediate | Nut Hypersensitivity | Central Nervous System Bacterial Infections | Plague | Pneumonia, Bacterial | Muscle Weakness | Hypokalemia | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis | Asthenia | Diarrhea | Conjunctivitis
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belarus, Belgium, Brazil, Canada, China, Colombia, Croatia, France, Georgia, Germany, Hungary, India, Ireland, Japan, Kazakhstan, Nepal, Netherlands, New Zealand, Pakistan, Peru, Portugal, Romania, Saudi Arabia, South Africa, Spain, United Kingdom, United States, Unknown Location, Uzbekistan
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: COVID-19|Capsule Opacification|Cataract|Conjunctivitis, Bacterial|Endophthalmitis|Extensively Drug-Resistant Tuberculosis|Fractures, Open|Influenza, Human|Otitis Externa|Otitis Media|Pneumonia|Pneumonia, Bacterial|Tuberculosis, Multidrug-Resistant|Tuberculosis, Pulmonary
Phase 2: Inflammation
Phase 1: Healthy Volunteers|Multiple Sclerosis|Muscular Dystrophy, Becker|Muscular Dystrophy, Duchenne|Scleroderma, General
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PARADIGM4TB | P2 |
Recruiting |
Tuberculosis, Pulmonary |
2027-02-24 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|COVID-19|Influenza, Human |
2026-02-01 |
|
| DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2026-01-31 |
|
| PIND 134134 | P3 |
Not yet recruiting |
Endophthalmitis|Cataract|Capsule Opacification |
2025-10-01 |
69% |